SEC
CLBT icon

Seven Eight Capital’s Cellebrite CLBT Stock Holding History

Seven Eight Capital’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-67,824
Closed -$1.14M – 129
2024
Q3 		$1.14M Buy
+67,824
New +$1.01M 0.1% 353

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Seven Eight Capital's CLBT Position: Q4 2024 in Review

Seven Eight Capital sold out of Cellebrite (CLBT) in Q4 2024, closing a stake of 67,824 shares — an estimated $1.14M sold.

Seven Eight Capital first reported a position in CLBT in Q3 2024 and held it in 1 quarter. The position peaked at $1.14M in Q3 2024. 191 funds tracked by Wall St. Rank hold CLBT as of Q4 2024.

  • Seven Eight Capital reported no remaining Cellebrite position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 67,824 Cellebrite shares in Q4 2024, an estimated $1.14M.
  • Seven Eight Capital first reported a position in Cellebrite in Q3 2024 and held it in 1 quarter.
  • Seven Eight Capital's Cellebrite position peaked at $1.14M in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Cellebrite as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.